The development of biologically sensitive field-effect transistors (FET) biosensors for the detection of biomarkers of Alzheimer's disease (AD) has gained significant attention in recent years. These biosensors have shown great potential in early diagnosis and drug screening studies due to their favorable characteristics, including sensitivity, specificity, portability, costeffectiveness, and high-throughput analysis capabilities. Many FET biosensors are constructed using standard, commercialized, and mass-produced devices, making them a popular choice in research. However, challenges remain in immobilizing biomolecular recognition elements onto the functionalized FET channel in a reproducible and stable manner. Selectivity is also a crucial factor for FET biosensors to be effective as a point-of-care tool. Recent advancements in nanotechnology, such as the integration of nanomaterials and nanostructures like SiNWs, CNTs, graphene, and metal nanoparticles, have greatly improved the performance of FET biosensors.